1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Hematological Disease: new trials by email Literature Review of Hematological Disease trials Research Report on Hematological Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies Pelabresib, Ruxolitinib - Myelofibrosis, Leukemia, Myelocytic, Acute | Phase 1 / Phase 2 | Completed | Constellation Pharmaceuticals | 336 | 2014-07-16 | 2026-06-04 |
| Cord Blood Transplantation for Patients With Cancer Melphalan, Fludarabine, Antithymocyte Globulin (ATG) - Hematological Disease | Phase 2 | Terminated | University of Chicago | 1 | 2010-04-01 | 2015-04-30 |
Hematologic Diseases (2) · Bone Marrow Diseases (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Precancerous Conditions (1) · Preleukemia (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
Hemic and Lymphatic Diseases (2) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Hemorrhagic Disorders (1) · Leukemia, Myeloid (1) · Thrombocytosis (1)
Antilymphocyte Serum (1) · Busulfan (1) · CPI-0610 (1) · Melphalan (1) · Whole-Body Irradiation (1) · fludarabine (1) · fludarabine phosphate (1) · ruxolitinib (1)
Constellation Pharmaceuticals (1) · University of Chicago (1)
United States (2) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
Andrew Artz, MD (1)
PMID 36881782, PMID 37530627, PMID 38259250
2018 (1)